India's Swine Flu Bravado
October 07, 2009 | Wednesday | News
India’s Swine
Flu Bravado
An unprepared health
system is endangering the nation’s future and the tardy
manner in which the country’s health authorities responded to
advance warning from global experts about the impending pandemic is
nothing but callousness towards the citizens
Narayanan Suresh, Group
Editor, BioSpectrum
Once in every 40 years, the world has witnessed a pandemic influenza
occurrence and the last one occurred in 1968. So when will the next one
strike the world? This was the question troubling a quiet and
unassuming, Dr John Boslego, director of the vaccine development
program at the Program for Appropriate Technology in Health (PATH), a
big but not-so-well known NGO based in Washington DC, in October 2007.
He was actually worried about the spread of the bird flu or avian
influenza virus (Influenza A H5N1).
Quickly, he prepared a monumental report that mapped the global
scenario in the case of such an outbreak happening in 2008 or 2009
which could kill up to 100 million people worldwide. He was worried
more about the development of a vaccine against H5N1 and ensure that it
was available in most of the developing countries. Based on his report,
the World Health Organization (WHO) commissioned global consultants,
McKinsey and prepared a business plan in February 2008 to build
capacity to produce pandemic influenza vaccines in all corners of the
world. India and the world, now ravaged by the totally unexpected
strain of swine flu or Influenza A H1N1 virus should thank Dr Boslego
for his foresight and wisdom. For, WHO estimated a global investment to
the tune of $3 billion (Rs 15,000 crore) to set up manufacturing
capacities to quickly make a vaccine against any pandemic influenza
within six months of it being declared as
“pandemic” (global spread) and make available over
13 billion doses of the vaccine.
More than two-thirds of the 32 companies with the capability to make
quality influenza vaccines were located in Europe and the US. Past
experience indicated that in the event of a global epidemic, the
countries where these vaccine manufacturing units were located would
lay the first claim on the products. Very little will be left for the
bulk of the global population who will need it the most in an emergency
situation. So WHO selected six companies —Serum Institute of
India, Pune, Birmex (Mexico), Bio Farma ( Indonesia), Government
Pharmaceutical Organization ( Thailand), Vabiotech ( Vietnam) and
Butantan, Brazil—to equip them with the expertise,
technical assistance and production capability to develop and
manufacture any new pandemic influenza vaccine. It will take
approximately six months from the time seed virus samples of a new
influenza strain is handed over to these companies to develop, test and
commercially make available the first set of vaccine.
WHO’s preparations have come in handy in the
current situation. The seed virus of H1N1, isolated from the
first set of patients in Mexico and California were quickly sent to the
newly identified companies too along with the supplies to the
vaccine makers in Europe and the US. Two other Indian companies,
Panacea Biotec (Delhi) and Bharat Biotech (Hyderabad) too have got the
seed virus from WHO.
Animal trials of the vaccine have started in India and in Australia,
China, Europe and the US small scale human trials too have begun. Most
probably, the first set of vaccines will be available in December.
Even if vaccines against H1N1 virus are available in India and the
world, it is not necessary that Indians will get it quickly. It is here
the folly or the negligence of Indian government comes in. The
government did not wake up to the danger of an impending influenza
epidemic in 2008 even though many health ministry officials have been
making frequent visits to the WHO headquarters in Geneva. There is no
strategic plan with the health ministry to tackle if the H1N1 virus
infects 350 to 400 million people, as predicted by Health Minister
Ghulam Nabi Azad in early August. Even a single percent mortality rate
implies that 3.5 to 4 million Indians could die of the disease in the
next two years.
The Health Minister has talked about importing the swine flu vaccine
from foreign companies. Most sensible governments abroad have already
placed orders for more than 300 million doses of the vaccine from just
one company, GSK. There is no word from Indian government about any
vaccine orders being placed. Even the three Indian vaccine companies
have so far got only oral assurances on vaccine procurement by the
government.
Firm buyer commitments are essential for vaccine companies because
current regulations do not permit open market sale of such essential
products. Till recently our government had monopolized Tamiflu, the
only medicine which can treat H1N1 infection now, keeping all the
national stocks with it. The Tamiflu stocks have depleted even as
Indian companies are exporting these to neighbouring countries. The
vaccine against H1N1 will have to stockpiled by public agencies as it
will be effective only for a year. If not used within 12 months, the
stocks will have to be destroyed and fresh supplies arranged for
emergency use.
This was the reason why most of the western governments placed advanced
orders worth $ 2 billion for the pandemic influenza (H5N1) vaccine soon
after the WHO report in early 2008 with the top vaccine manufacturers.
So these vaccine manufacturers in Europe and USA have had a head start
over their counterparts in developing nations like India. Australia has
ordered 42 million doses of the H1N1 vaccine to the
country’s only manufacturer, CSL Ltd, to vaccinate each of
her 21 million citizens. The Beijing government has ordered 10 million
doses of the vaccine from the country leading vaccine maker, Sinovac.
Time is running out for our country. There are several technological
challenges in increasing the quantity of the H1N1 vaccine when it is
approved by the regulators for large scale use. The influenza virus
grows very well in chicken eggs and alternate technologies to make it
such as the cell culture method and recombinant DNA technology are
untested.
There are only four companies in the world which produce the special
fertile eggs, called Specific Pathogen Free (SPF) eggs, which will be
used to make the H1N1 vaccine. Two of these manufacturers are in the
USA and the third one is in Germany. The fourth one, Venkateshwara
Hatcheries, the only Asian company with the expertise to make SPF eggs,
is in Pune. The capacity to produce these SPF eggs, each of which costs
more than Rs 30-50 is limited. In a year, the company may be able to
spare only 30 to 40 million eggs for this purpose to human vaccine
makers. These eggs are used mostly in the manufacture of poultry and
cattle vaccine. Each egg could be used to make just one dose of the
influenza vaccine. Due to this capacity constraint within the country,
it may be possible to vaccine less than 10 percent of Indians in a
year. India will be lucky if other nations spare their vaccine stocks
and rush to our aid if the need arises.
Of course it may be too much to expect India’s health
ministry officials to make strategic plans to stock pile essential
vaccines in larger public interest. The ministry has been callous in
neglecting the country’s future citizens, born in the last
two to three years. Only 80 percent of 27 million new born children
born in each of the last two years got their first shots of essential
vaccines under the National Immunization Programmes. The ministry could
not find more than Rs 65 crore to buy these essential vaccines from the
manufacturers in the country and created a shortage. The harmful
effects of not providing essential vaccination to more than 10 million
children in the last two years will be evident in the next few years
when infections like H1N1 spread across the country rapidly.
Sitting far away from the H1N1 cities of India, Dr Boslego, had the
foresight to warn the humanity against the impending danger.
India’s policy makers did not listen to him for nearly two
years. It is not too late even now. Instead of patting itself on the
back for the limited number of deaths caused by the swine flu
virus so far, the government will do the nation a big service if it
cranks up its procurement machinery and make available resources and
announce its commitment to safeguard the health of its citizens
immediately.